ArticleGastro hep advances2026

Vascular Endothelial Growth Factor Receptor 2-Targeted Therapy Suppresses the Progression of Alpha-Fetoprotein-Positive Hepatocellular Carcinoma After Combination Therapy With Anti-Programmed Death-Ligand 1 and Anti-Vascular Endothelial Growth Factor-A Antibodies.

Gen Sugiyama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.